{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:09:41Z","timestamp":1767337781040,"version":"3.41.2"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pulmonary hypertension (PH) is one of the significant complications of sarcoidosis. In the clinical classification of PH proposed in the recent world symposium of PH 2018, sarcoidosis-associated PH is classified in Group 5. The mechanisms of sarcoidosis-associated PH are very heterogeneous. There is no evidence of effective treatment for this condition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>We report a case of a 46-year-old female who developed severe pulmonary hypertension due to sarcoidosis. Her haemodynamics, exercise capacity, and functional class remarkably improved after the treatment with pulmonary arterial hypertension (PAH) targeted drugs including macitentan and tadalafil and secondary immunosuppressive therapy with corticosteroids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This case emphasizes the importance of considering the underlying mechanisms of sarcoidosis-associated PH in order to choose appropriate treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaa454","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T16:34:07Z","timestamp":1608136447000},"source":"Crossref","is-referenced-by-count":4,"title":["Combination therapy with pulmonary arterial hypertension targeted drugs and immunosuppression can be a useful strategy for sarcoidosis-associated pulmonary hypertension: a case report"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-8165","authenticated-orcid":false,"given":"Keiko","family":"Sumimoto","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8430-2123","authenticated-orcid":false,"given":"Yu","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Emoto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-Ichi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2021062103184693900_ytaa454-B1","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1378\/chest.129.5.1246","article-title":"Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis","volume":"129","author":"Handa","year":"2006","journal-title":"Chest"},{"key":"2021062103184693900_ytaa454-B2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0034-1376863","article-title":"Sarcoidosis-associated pulmonary hypertension and lung transplantation for sarcoidosis","volume":"35","author":"Shino","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"2021062103184693900_ytaa454-B3","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2021062103184693900_ytaa454-B4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1055\/s-0037-1603767","article-title":"Sarcoidosis-associated pulmonary hypertension","volume":"38","author":"Shlobin","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"2021062103184693900_ytaa454-B5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"2021062103184693900_ytaa454-B6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial","volume":"145","author":"Baughman","year":"2014","journal-title":"Chest"},{"key":"2021062103184693900_ytaa454-B7","first-page":"w14677.","article-title":"Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial","volume":"148","author":"Hostettler","year":"2018","journal-title":"Swiss Med Wkly"},{"key":"2021062103184693900_ytaa454-B8","first-page":"139","article-title":"Ambrisentan for sarcoidosis associated pulmonary hypertension","volume":"28","author":"Judson","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2021062103184693900_ytaa454-B9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.healun.2007.11.576","article-title":"Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?","volume":"27","author":"Milman","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"2021062103184693900_ytaa454-B10","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1378\/chest.128.3.1483","article-title":"Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension","volume":"128","author":"Sulica","year":"2005","journal-title":"Chest"},{"key":"2021062103184693900_ytaa454-B11","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2021062103184693900_ytaa454-B12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/CPM.0000000000000252","article-title":"Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis, and treatment","volume":"25","author":"Duong","year":"2018","journal-title":"Clin Pulm Med"},{"key":"2021062103184693900_ytaa454-B13","doi-asserted-by":"crossref","first-page":"1700465","DOI":"10.1183\/13993003.00465-2017","article-title":"Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"2021062103184693900_ytaa454-B14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1378\/chest.130.5.1481","article-title":"Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment","volume":"130","author":"Fisher","year":"2006","journal-title":"Chest"},{"key":"2021062103184693900_ytaa454-B15","doi-asserted-by":"crossref","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/1\/ytaa454\/38710004\/ytaa454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/1\/ytaa454\/38710004\/ytaa454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T03:19:00Z","timestamp":1624245540000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytaa454\/6039084"}},"subtitle":[],"editor":[{"given":"Grey","family":"Belinda","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Nistor","family":"Dan Octavian","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Shigeta","family":"Ayako","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Tardo","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Mehta","family":"Vishal Shahil","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaa454","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,12,16]]},"article-number":"ytaa454"}}